Signal Transduction And Targeted Therapy雜志是一本國際頂尖期刊，是一本開放獲取期刊。該雜志近三年影響因子分別為：2023年40.8、2022年39.3、2021年38.104。該雜志近三年CiteScore評價分區分別為：2023年44.5區、2022年31.5區、2021年18.4區。該刊專門致力于推進BIOCHEMISTRY & MOLECULAR BIOLOGY領域的研究，涵蓋了BIOCHEMISTRY & MOLECULAR BIOLOGY領域的各個方面，匯集所有專家，促進BIOCHEMISTRY & MOLECULAR BIOLOGY領域的更好協作和信息共享。該期刊為BIOCHEMISTRY & MOLECULAR BIOLOGY領域的科研人員提供了一個高影響力的論壇，使該領域的科研人員、從業人員和學生能夠接觸到尖端的經驗性調查分析、學術對話以及行業科研成果的最新發展。通過收錄高質量的原創論文和評論論文，促進BIOCHEMISTRY & MOLECULAR BIOLOGY領域的應用與發展。該期刊還將該領域的創新與應用，以提高研究的質量和實用性。近年來在該刊上發文的國家和地區主要有：USA（發文量96）、Turkey（發文量2）、Taiwan（發文量1）、Switzerland（發文量1）、Sweden（發文量3）、Spain（發文量6）。
Signal Transduction And Targeted Therapy是一本由Springer Nature出版社發行的知名BIOCHEMISTRY & MOLECULAR BIOLOGY期刊。該雜志社聯系方式CAMPUS, 4 CRINAN ST, LONDON, ENGLAND, N1 9XW。審稿過程是確保期刊質量的關鍵環節。Signal Transduction And Targeted Therapy雜志的審稿速度平均需要 5 Weeks 。這一時間周期既體現了編輯部對稿件質量的嚴格把關，也反映了審稿專家對學術研究的尊重和支持。在這個過程中，作者們可以充分利用這段時間對自己的研究成果進行完善和優化，以提高論文的質量和影響力。如果您對該期刊感興趣，并希望了解更多關于投稿流程、投稿要求和技巧的信息，您可以咨詢本站的客服老師，我們將幫助您了解期刊的投稿要求、審稿流程以及可能遇到的問題，并根據您的具體情況提供相應的建議和解決方案。
Signal Transduction And Targeted Therapy雜志近期中國學者發表的論文主要有：
-
1、Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants
Author: Wang, Qian; Yang, Chenchen; Yin, Li; Sun, Jing; Wang, Wei; Li, Hengchun; Zhang, Zhengyuan; Chen, Si; Liu, Bo; Liu, Zijian; Shi, Linjing; Liu, Xiaolin; Guan, Suhua; Wang, Chunhua; Qu, Linbing; Feng, Ying; Niu, Xuefeng; Feng, Liqiang; Zhao, Jincun; Li, Pingchao; Chen, Ling; Zhong, Nanshan
-
2、Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma
Author: Hu, Junhui; Tan, Ping; Ishihara, Moe; Bayley, Nicholas A.; Schokrpur, Shiruyeh; Reynoso, Jeremy G.; Zhang, Yangjun; Lim, Raymond J.; Dumitras, Camelia; Yang, Lu; Dubinett, Steven M.; Jat, Parmjit S.; Van Snick, Jacques; Huang, Jiaoti; Chin, Arnold I.; Prins, Robert M.; Graeber, Thomas G.; Xu, Hua; Wu, Lily
-
3、Combination therapy with saxagliptin and vitamin D for the preservation of beta-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial
Author: Yan, Xiang; Li, Xia; Liu, Bingwen; Huang, Jiaqi; Xiang, Yufei; Hu, Yuhang; Tang, Xiaohan; Zhang, Ziwei; Huang, Gan; Xie, Zhiguo; Zhou, Houde; Liu, Zhenqi; Wang, Xiangbing; Leslie, Richard David; Zhou, Zhiguang
-
4、Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions
Author: Ma, Jun; Li, Yanan; Yang, Xiangyu; Liu, Kai; Zhang, Xin; Zuo, Xianghao; Ye, Runyu; Wang, Ziqiong; Shi, Rufeng; Meng, Qingtao; Chen, Xiaoping
-
5、RBM4 dictates ESCC cell fate switch from cellular senescence to glutamine-addiction survival through inhibiting LKB1-AMPK-axis
Author: Chen, Lei; Zhang, Wenjing; Chen, Dan; Yang, Quan; Sun, Siwen; Dai, Zhenwei; Li, Zhengzheng; Liang, Xuemei; Chen, Chaoqun; Jiao, Yuexia; Zhi, Lili; Zhao, Lianmei; Zhang, Jinrui; Liu, Xuefeng; Zhao, Jinyao; Li, Man; Wang, Yang; Qi, Yangfan
-
6、Preventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2
Author: Xu, Zhijian; Shi, Danrong; Han, Jian-Bao; Ling, Yun; Jiang, Xiangrui; Lu, Xiangyun; Li, Chuan; Gong, Likun; Ge, Guangbo; Zhang, Yani; Zang, Yi; Song, Tian-Zhang; Feng, Xiao-Li; Tian, Ren-Rong; Ji, Jia; Zhu, Miaojin; Wu, Nanping; Wu, Chunhui; Wang, Zhen; Xu, Yechun; Peng, Cheng; Zheng, Min; Yang, Junling; Du, Feifei; Wu, Junliang; Wang, Peipei; Shen, Jingshan; Zhang, Jianliang; Zheng, Yong-Tang; Yao, Hangping; Zhu, Weiliang
